Name | Number of supported studies | Average coverage | |
---|---|---|---|
regulatory T cell | 11 studies | 26% ± 13% | |
macrophage | 10 studies | 20% ± 6% | |
non-classical monocyte | 8 studies | 24% ± 11% | |
classical monocyte | 5 studies | 25% ± 8% | |
epithelial cell | 5 studies | 36% ± 3% | |
conventional dendritic cell | 4 studies | 26% ± 8% | |
enterocyte | 4 studies | 26% ± 4% | |
oligodendrocyte | 4 studies | 22% ± 6% | |
platelet | 4 studies | 23% ± 3% | |
pancreatic A cell | 3 studies | 33% ± 9% | |
ciliated cell | 3 studies | 28% ± 12% | |
type I pneumocyte | 3 studies | 23% ± 5% | |
natural killer cell | 3 studies | 19% ± 2% | |
goblet cell | 3 studies | 21% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 2127.06 | 577 / 578 | 100% | 81.97 | 1154 / 1155 |
intestine | 100% | 2528.18 | 965 / 966 | 100% | 81.07 | 525 / 527 |
liver | 100% | 2553.63 | 226 / 226 | 100% | 100.91 | 404 / 406 |
thymus | 100% | 2295.80 | 653 / 653 | 99% | 41.77 | 600 / 605 |
stomach | 99% | 1793.01 | 357 / 359 | 100% | 72.66 | 285 / 286 |
bladder | 100% | 2103.29 | 21 / 21 | 99% | 65.90 | 498 / 504 |
esophagus | 100% | 1794.19 | 1445 / 1445 | 98% | 65.94 | 180 / 183 |
kidney | 100% | 1586.60 | 89 / 89 | 98% | 57.23 | 884 / 901 |
breast | 100% | 1421.56 | 459 / 459 | 97% | 49.11 | 1081 / 1118 |
pancreas | 95% | 861.47 | 312 / 328 | 99% | 74.10 | 176 / 178 |
uterus | 96% | 777.62 | 163 / 170 | 96% | 59.28 | 440 / 459 |
prostate | 100% | 1318.16 | 245 / 245 | 91% | 29.17 | 459 / 502 |
adrenal gland | 100% | 3003.62 | 258 / 258 | 87% | 34.70 | 201 / 230 |
skin | 100% | 1860.13 | 1808 / 1809 | 85% | 36.80 | 403 / 472 |
ovary | 98% | 757.95 | 177 / 180 | 86% | 26.03 | 371 / 430 |
brain | 88% | 733.47 | 2336 / 2642 | 44% | 10.31 | 310 / 705 |
adipose | 100% | 1615.33 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 52.72 | 29 / 29 |
spleen | 100% | 2216.03 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 62.88 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 18.44 | 1 / 1 |
blood vessel | 100% | 1629.75 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 2530.87 | 904 / 929 | 0% | 0 | 0 / 0 |
heart | 94% | 702.74 | 807 / 861 | 0% | 0 | 0 / 0 |
muscle | 92% | 1471.67 | 740 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 44% | 14.28 | 35 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001525 | Biological process | angiogenesis |
GO_0051170 | Biological process | import into nucleus |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0045765 | Biological process | regulation of angiogenesis |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0043068 | Biological process | positive regulation of programmed cell death |
GO_0030154 | Biological process | cell differentiation |
GO_0006915 | Biological process | apoptotic process |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0016020 | Cellular component | membrane |
GO_0005635 | Cellular component | nuclear envelope |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | HTATIP2 |
Protein name | Oxidoreductase HTATIP2 (EC 1.1.1.-) (30 kDa HIV-1 TAT-interacting protein) (HIV-1 TAT-interactive protein 2) Oxidoreductase HTATIP2 |
Synonyms | TIP30 CC3 |
Description | FUNCTION: Oxidoreductase required for tumor suppression. NADPH-bound form inhibits nuclear import by competing with nuclear import substrates for binding to a subset of nuclear transport receptors. May act as a redox sensor linked to transcription through regulation of nuclear import. Isoform 1 is a metastasis suppressor with proapoptotic as well as antiangiogenic properties. Isoform 2 has an antiapoptotic effect. . |
Accessions | ENST00000419348.6 [Q9BUP3-3] ENST00000443524.6 [Q9BUP3-1] ENST00000532505.1 [Q9BUP3-2] ENST00000530266.5 [Q9BUP3-2] Q9BUP3 ENST00000531058.1 ENST00000451739.7 [Q9BUP3-1] ENST00000421577.6 [Q9BUP3-1] ENST00000532081.1 [Q9BUP3-2] E9PI87 |